Multiple Myeloma section

Multiple Myeloma News & Features

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

Antibacterial prophylaxis with the flouroquinolone, ciprofloxacin, substantially reduced the risk of bacteremia and neutropenic fever in patients with multiple myeloma or lymphoma undergoing high-dose chemotherapy and auto-HSCT.

MRD Negativity Associated With Prolonged Survival in Myeloma

MRD Negativity Associated With Prolonged Survival in Myeloma

Minimal residual disease (MRD) negativity after treatment is associated with prolonged overall survival in patients with newly diagnosed multiple myeloma.

Study Assesses Infection Risk With Myeloma Therapies

Study Assesses Infection Risk With Myeloma Therapies

Researchers have determined the risk of infection for immunomodulatory drug-based therapy and proteasome inhibitor-based therapy with respect to treatment phase in patients with multiple myeloma.

Daratumumab Combo Improves PFS in Relapsed/Refractory Myeloma

Daratumumab Combo Improves PFS in Relapsed/Refractory Myeloma

Daratumumab plus bortezomib and dexamethasone improves progression-free survival in multiple myeloma.

Daratumumab Plus Len-Dex an Encouraging Combo for Multiple Myeloma

Daratumumab Plus Len-Dex an Encouraging Combo for Multiple Myeloma

Daratumumab plus lenalidomide and dexamethasone resulted in rapid, deep, durable responses in patients with multiple myeloma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs